首页 | 本学科首页   官方微博 | 高级检索  
     

肝癌合并门静脉癌栓手术疗效及预后分析
引用本文:郭兴军,郑启昌,宋自芳,左克强,尚丹,张磊.肝癌合并门静脉癌栓手术疗效及预后分析[J].腹部外科,2005,18(4):220-221.
作者姓名:郭兴军  郑启昌  宋自芳  左克强  尚丹  张磊
作者单位:430022,武汉,华中科技大学同济医学院附属协和医院普外科;430022,武汉,华中科技大学同济医学院附属协和医院普外科;430022,武汉,华中科技大学同济医学院附属协和医院普外科;430022,武汉,华中科技大学同济医学院附属协和医院普外科;430022,武汉,华中科技大学同济医学院附属协和医院普外科;430022,武汉,华中科技大学同济医学院附属协和医院普外科
摘    要:目的探讨影响肝癌合并门静脉癌栓病人手术疗效和预后的因素。方法回顾性分析我院2000年~2003年收治的68例肝癌合并门静脉癌栓病人的临床资料。分别按术后是否加用化疗、有无合并肝硬变、肿瘤大小及Child-Pugh分级等进行分组研究,比较各组间术后不同的疗效。结果手术切除加化疗组中位生存时间为17.8月,术后6个月及1、2、3年生存率分别为80.4%及64.7%、47.1%、31.4%;单纯手术切除组分别为14.5月和70.6%、52.4%、29.4%、5.9%。手术切除加化疗组疗效均明显优于单纯手术切除组(P<0.05)。结论手术切除加术后化疗或栓塞治疗是治疗肝癌合并门静脉癌栓病人的有效治疗方案。肝硬变、肿瘤大小及Child-Pug分级与病人术后生存时间相关,可作为判断预后的重要指标。

关 键 词:肝肿瘤    肝细胞  门静脉  肝切除术  药物疗法  联合
修稿时间:2005年1月28日

Surgical effectiveness and prognosis of hepatocellular carcinoma with portal vein tumor thrombus
GUO Xing-jun,ZHENG Qi-chang,SONG Zi-fang,et al..Surgical effectiveness and prognosis of hepatocellular carcinoma with portal vein tumor thrombus[J].Journal of Abdominal Surgery,2005,18(4):220-221.
Authors:GUO Xing-jun  ZHENG Qi-chang  SONG Zi-fang  
Affiliation:GUO Xing-jun,ZHENG Qi-chang,SONG Zi-fang,et al.Department of General Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China
Abstract:ObjectiveTo study the factors influencing the prognosis and surgical effectiveness of hepatocellular carcinoma(HCC)with portal vein tumor thrombus(PVTT).MethodsThe clinical data of 68 cases of HCC with PVTT from 2001 to 2004 were analyzed retrospectively.All patients were subjected to surgical operation.In terms of postoperative chemotherapy,liver cirrhosis and tumor size,Child-Pugh stage,the cases were divided two groups and analyzed respectively.ResultsIn the group of surgical resection plus postoperative chemotherapy,the median survival time was 17.8 months and the postoperative 0.5-,1-,2-,3-year survival rates were 80.4%,64.7%,47.1% and 31.4% respectively.In the group of simple surgical resection,the median survival time was 14.5 months,and the postoperative 0.5-,1-,2-,3-year survival rates were 70.6%,52.4%,29.4% and 5.9% respectively.There were significant difference between the two groups(P<(0.05)).ConclusionSurgical resection combined with postoperative chemotherapy or chemoembolization is an effective therapy for the HCC with PVTT;Liver cirrhosis,tumor size and Child-Pugh stage may be important parameters to estimate the prognosis of HCC with PVTT.
Keywords:Liver neoplasms  Carcinoma  hepatocellular  Portal vein  Hepatectomy  Drug therapy  combination
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号